Studies have shown that TUG1 and MEG3 expression levels are reduced in human glioma tissues, with TUG1 promoting cell apoptosis and suppressing proliferation, migration, and invasion, while GAS5 was identified as a suppressor that enhances glioma therapy efficacy by directly targeting miR-222. Here, GAS5 is linked to central nervous system cancer.